MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-18-2023
Aptinyx Cash Conversion Cycle 2011-2026 | APTX
Annual Cash Conversion Cycle Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 46.9 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.9 | 46.9 | 46.9 |
Quarterly Cash Conversion Cycle Aptinyx
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 11.7 | - | 91.2 | 47.9 | 39.1 | - | 43.3 | 43.8 | 52.4 | - | 55.9 | 24.8 | 28.1 | - | 71 | 29.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 91.2 | 11.7 | 44.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
284 | $ 232.08 | 3.29 % | $ 411 B |  USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
387 | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
-1.56 K | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Adagene
ADAG
|
53.8 | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADMA Biologics
ADMA
|
355 | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-4.31 K | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
-6 K | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Alector
ALEC
|
-13.8 | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Alkermes plc
ALKS
|
299 | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Altimmune
ALT
|
15.1 K | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Amgen
AMGN
|
217 | $ 388.16 | 2.33 % | $ 209 B | USA |